AMPK is considered a major target for drugs to combat the growing epidemic of metabolic disorders (Hardie et al., 2012) because AMPK activation elicits metabolic responses expected to counteract the physiological or metabolic abnormalities associated with obesity, insulin resistance, and type 2 diabetes. This evidence concerns the gene PRKAA2 and obesity due to melanocortin 4 receptor deficiency.